Literature DB >> 17680359

International Study of Health Care Organization and Financing for end-stage renal disease in France.

Isabelle Durand-Zaleski1, Christian Combe, Philippe Lang.   

Abstract

The major features of ESRD management in France include the predominance of hemodialysis and the resulting competition for dialysis stations. In 2003, the prevalence of ESRD in France was 0.087%. Of the 52,000 ESRD patients, 30,882 were receiving dialysis and 21,233 had functioning renal transplants. The annual expenditure per ESRD patient in 2003 was estimated at euro40,975. Autodialysis, at euro49,133 per patient per year, was much less expensive than dialyzing in-center at either a public or private facility (euro111,006 and euro75,125, respectively). Transplant activity in France has rapidly increased in recent years, reaching 22 donors per million population in 2005.

Entities:  

Mesh:

Year:  2007        PMID: 17680359     DOI: 10.1007/s10754-007-9025-8

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  18 in total

1.  Geographic disparities in access to organ transplant in France.

Authors:  Françoise Roudot-Thoraval; Philippe Romano; Francis Spaak; Didier Houssin; Isabelle Durand-Zaleski
Journal:  Transplantation       Date:  2003-11-15       Impact factor: 4.939

2.  Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.

Authors:  Francesco Locatelli; Pedro Aljama; Peter Bárány; Bernard Canaud; Fernando Carrera; Kai-Uwe Eckardt; Walter H Hörl; Iain C Macdougal; Alison Macleod; Andrzej Wiecek; Stewart Cameron
Journal:  Nephrol Dial Transplant       Date:  2004-05       Impact factor: 5.992

3.  [Regional disparities in the management of dialysed patients in France in 2003].

Authors:  Françoise Macron-Noguès; Michel Vernay; Eric Ekong; Bénédicte Thiard; Benoît Salanave; Pierre Fender; Hubert Allemand
Journal:  Nephrol Ther       Date:  2005-09-15       Impact factor: 0.722

4.  International Study of Health Care Organization and Financing of renal services in England and Wales.

Authors:  Tricia Nicholson; Paul Roderick
Journal:  Int J Health Care Finance Econ       Date:  2007-12

5.  International study of health care organization and financing: development of renal replacement therapy in Germany.

Authors:  Werner Kleophas; Helmut Reichel
Journal:  Int J Health Care Finance Econ       Date:  2007-09

6.  Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients.

Authors:  C Combe; P Chauveau; M Laville; D Fouque; R Azar; N Cano; B Canaud; H Roth; X Leverve; M Aparicio
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

7.  Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Erwin Hecking; Jennifer L Bragg-Gresham; Hugh C Rayner; Ronald L Pisoni; Vittorio E Andreucci; Christian Combe; Roger Greenwood; Keith McCullough; Harold I Feldman; Eric W Young; Philip J Held; Friedrich K Port
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

8.  Death after withdrawal from dialysis: the most common cause of death in a French dialysis population.

Authors:  Béatrice Birmelé; Maud François; Josette Pengloan; Patrick Français; Didier Testou; Georges Brillet; Didier Lechapois; Serge Baudin; Olivier Grezard; Jean-Louis Jourdan; Mohamed Fodil-Cherif; Mohamed Abaza; Luc Dupouet; Gilles Fournier; Hubert Nivet
Journal:  Nephrol Dial Transplant       Date:  2004-03       Impact factor: 5.992

Review 9.  Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease.

Authors:  Wim Van Biesen; Norbert Lameire; Patrick Peeters; Raymond Vanholder
Journal:  Int J Health Care Finance Econ       Date:  2007-09

10.  The organization and financing of kidney dialysis and transplant care in the United States of America.

Authors:  Richard A Hirth
Journal:  Int J Health Care Finance Econ       Date:  2007-12
View more
  8 in total

Review 1.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

2.  International Study of Health Care Organization and Financing of renal services in England and Wales.

Authors:  Tricia Nicholson; Paul Roderick
Journal:  Int J Health Care Finance Econ       Date:  2007-12

3.  International study of health care organization and financing: development of renal replacement therapy in Germany.

Authors:  Werner Kleophas; Helmut Reichel
Journal:  Int J Health Care Finance Econ       Date:  2007-09

4.  The financing and organization of medical care for patients with end-stage renal disease in Sweden.

Authors:  Björn Wikström; Michael Fored; Margaret A Eichleay; Stefan H Jacobson
Journal:  Int J Health Care Finance Econ       Date:  2007-12

Review 5.  Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease.

Authors:  Wim Van Biesen; Norbert Lameire; Patrick Peeters; Raymond Vanholder
Journal:  Int J Health Care Finance Econ       Date:  2007-09

6.  Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.

Authors:  Hayley Bennett; Phil McEwan; Karina Hamilton; Karl O'Reilly
Journal:  BMC Nephrol       Date:  2019-04-23       Impact factor: 2.388

7.  Economic Burden of ESRD to the Malaysian Health Care System.

Authors:  Hirman Ismail; Mohd Rizal Abdul Manaf; Abdul Halim Abdul Gafor; Zaki Morad Mohamad Zaher; Adriana Irawati Nur Ibrahim
Journal:  Kidney Int Rep       Date:  2019-05-29

8.  Barriers to successful implementation of care in home haemodialysis (BASIC-HHD):1. Study design, methods and rationale.

Authors:  Anuradha Jayanti; Alison J Wearden; Julie Morris; Paul Brenchley; Inger Abma; Steffen Bayer; James Barlow; Sandip Mitra
Journal:  BMC Nephrol       Date:  2013-09-17       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.